Mitomycin C
The Nordic Group obtains the marketing rights for Mitomycin C Kyowa in Central & Eastern Europe.
The Nordic Group obtained on May 1st, 2010, the exclusive marketing rights for Mitomycin C, an antineoplastic agent from Kyowa Hakko Kirin Co. Ltd. in the Czech Republic, the Slovak Republic, Hungary, Poland, and Bulgaria, as well as Russia, the Ukraine and Georgia.
Mitomycin C Kyowa was launched in Central & Eastern European countries about 25 years ago and until now, it has been commercialized through different distributor channels.
Mitomycin C Kyowa is prescribed in the treatment of malignant neoplastic diseases, including disseminated adenocarcinoma of the stomach, pancreas and colon. However, its main use is as an instillation after resection in the treatment of non-muscle invasive bladder cancer.
The Nordic Group is a pan European, fully integrated pharmaceutical company focused on hospital products in a few, selected therapeutic areas that have significant unmet medical needs.